Drug Repurposing, Rescue, and Repositioning

For Authors

Our dynamic Author Benefits Program provides you with end-to-end benefits that ensure your hard work pays off and your published manuscript gets the attention it deserves not just upon publication, but permanently.

Drug Repurposing, Rescue, and Repositioning (DRRR) is a newly developed and dedicated section that will now be featured bi-annually in the well-established and MEDLINE-indexed journal ASSAY and Drug Development Technologies. These special peer-reviewed collection of papers present techniques and tools for finding new uses for approved drugs – particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

This authoritative, rapidly peer-reviewed special section will feature original papers, application-oriented technology reviews, and reports in methodology and technology application including:

Pathway analysis and bioinformatics to identify and exploit drug promiscuity

In silico technologies to identify alternate drug targets

"Big Data" mining and side effect pattern analysis in clinical and healthcare repositories

Drug repurposing towards neglected and orphan diseases

Drug reformulation and alternative routes of administration

The DRRR section is under the leadership of Dr. Hermann Mucke, Hermann Mucke Pharma Consultancy e.U.

SUBMISSION OF MANUSCRIPTSManuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication, elsewhere except in the form of an abstract. Prior abstract publications should be described in the form of a footnote to the manuscript title. Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal, unless otherwise noted. By submitting a manuscript to the Journal, the author(s) agree(s) to these conditions. Certain exceptions from this rule apply (ex: some government employees, or work presented on behalf of governmental agencies).

NOTE:

All submissions to Drug Repurposing, Rescue, and Repositioning are being managed through our online peer review system for Assay and Drug Development Technologies using the following URL:

All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Drug Repurposing, Rescue, and Repositioning. For authors whose native language is not English, we suggest using a service that can aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service with a subsidy from the author prior to official submission (contact AuthorServices@liebertpub.com). It is important to note that employing the use of the Publisher’s service does not guarantee acceptance of any paper. All submissions are subject to peer review.

PEER REVIEW

All submissions to the Journal are subject to peer review. Authors are encouraged, but not required, to supply the names and email addresses of three to four individuals who are considered qualified to review the submitted material, as well as the names of individuals whom the authors would prefer not be selected as a reviewer. However, the review selection is ultimately at the discretion of the Editor.

AUTHORSHIP

All authors, including the co-authors, should be responsible for a significant part of the manuscript. All authors and co-authors should have taken part in writing the manuscript, reviewing it, and revising its intellectual and technical content. Any author whose name appears on a paper assumes responsibility and accountability for the results.

It is incumbent upon the submitting author to ensure the accuracy and inclusion of all contributing authors’ names and affiliations upon original submission of the paper. Once a paper is accepted for publication, changes in authorship are NOT permitted. Changes in authorship after publication are strictly prohibited.

Working Groups or Committees as AuthorsWorking Groups and/or Committees should NOT be listed as an author. Instead, the name of the Working Group and/or Committee and all of the participants, should be listed in the Acknowledgments section of the manuscript.

Corresponding Authorship

It is the Journal’s policy that only ONE corresponding author is listed on a paper. This designation should be determined at the time of submission. Additions to corresponding authors are not permitted after acceptance or in page proofs.

PREPARATION OF MANUSCRIPTS

Word Limits

Article Type

Maximum Word Limit*

Abstract Word Limit

Maximum #

of References

Maximum # of Figures

Maximum # of Tables

Original

5,000-6,000

250

100

12

6

Invited Review

8,000-12,000

250

250

12

6

Methods

5,000-6,000

250

100

6

6

Case Study

2,000-3,000

250

20

6

2

Commentary

1,000

150

(Inclusion of abstract is optional)

4

1

1

Letters to the Editor

500

N/A

4

1 OR

1

*These limits relate to the text of the manuscript; word limits do NOT include the abstract, figure and/or table legends, acknowledgments, disclosures, or references

All text submissions must be provided in Word. Do not submit PDFs of the manuscript or any text files. Submissions containing PDFs of text files will be returned without review.

All manuscript pages should be double spaced.

Include a title page that contains:

mdash; The full title of the manuscript— All contributing authors’ full names— All contributing author’s complete affiliations— A short title of no more than 50 characters, including spaces— At least 4 (four) keywords [maximum of 8 (eight)]

Supply an abstract as the second page of text.

After the abstract, the text should be constructed as follows:

Text:Organize the text as follows: Introduction;Materials and Methods; Results; Discussion; Conclusions; Acknowledgments; Disclosure; and References. At the first usage of a term, spell out the term and then provide the abbreviation or acronym in parentheses. Thereafter, use the abbreviation/acronym alone.

Acknowledgments: The author should acknowledge only those people and institutions that have made significant contributions to the study.

Disclosure Statement: Immediately following the Acknowledgments section, include a section entitled “Author Disclosure Statement.” In this portion of the paper, authors must disclose any commercial associations that might create a conflict of interest in connection with submitted manuscripts. This statement should include appropriate information for EACH author, thereby representing that competing financial interests of all authors have been appropriately disclosed according to the policy of the Journal. It is important that all conflicts of interest, whether they are actual or potential, be disclosed. This information will remain confidential while the paper is being reviewed and will not influence the editorial decision. If no conflicts exist, the authors must state “No competing financial interests exist.”

References: The references should be cited in the text using the American Medical Association’s (AMA) reference style.

Items are listed numerically in the order they are cited in the text

Include up to six (6) authors

For references containing more than six authors, list the first three (3), followed by et al

If no author is listed, start with the article/book title

Journal titles in the reference listed should be abbreviated according to Medline

For accepted papers not yet published, cite the journal and add "in press." If references to personal communications or unpublished data are used, cite them parenthetically in the text, not in the references. Sources for personal communications must provide written approval at the time of submission. Authors are responsible for the accuracy of references.

Abstract: Doudican NA. et al. In vitro validation of rationally designed therapeutic based on drug repositioning and combinations . Abstract number 2104 from the American Association for Cancer Research Annual Meeting; Washington DC, April 6–10, 2013.

Website references: Please follow this structure for website references, including capitalization and punctuation:

List all Authors’ (or) Editors’ names (last name first, followed by first and middle initials). Conference title. Date of conference. Location of conference. City of publisher: Publisher; Year of publication. Complete number of pages in proceedings book.

• Correspondence address: After the references, provide the name, address, and e-mail of the person to whom all correspondence should be directed. This information will be included at the end of the references in the final published version of the article.

Unpublished MaterialWhen a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list. Personal communications should also be listed parenthetically in text, and should contain the first initial and last name of the contact, as well as the month and year of the communication. Published manuscripts, and those that have been accepted and are pending publication, should be cited in the reference list.

TABLES

Submit table(s), each with its own title, as a separate file from the text of the manuscript. Use Arabic numerals to number tables. Table legends and/or footnotes should be double-spaced.

FIGURES

Prepare a separate list of figure legends, double-spaced, at the end of the manuscript file.

Please follow these guidelines for submitting figures.

Do NOT embed art files into a Word or PDF document.

Line illustrations should be submitted at a minimum of 900 dpi.

Halftones and color should be submitted at a minimum of 300 dpi.

Black and White art must be submitted as grayscale—not RGB.

Save as either TIFF or EPS files.

Color art must be saved as CYMK—not RGB.

PowerPoint and Excel files cannot be accepted.

Name figure files using only alphanumeric characters. Do not use symbols, dots, or dashes.

File names should be formatted with first author’s last name and the figure number. (Ex: SmithFig1).

COLOR FIGURES

The cost of printing figures in color must be subsidized by the author(s). Cost estimates are available from the Publisher upon request.

COPYRIGHT

Upon acceptance of any manuscript, all authors will receive a follow-up email with instructions on how to complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors’ email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications.

The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright.

If a co-author does not receive the proper email, the pending copyright form may be completed by logging on to the Manuscript Central system using the author’s credentials. Click on Author Center and complete the forms located under “Manuscripts I Have Coauthored,” or “Manuscripts with Decisions” if you are listed as the corresponding author on the paper.

Failure by all authors to submit this form will result in a delay in publication.

INFORMED CONSENT, STUDY ETHICS APPROVAL, AND SUBJECT CONFIDENTIALITY

Patients and Study Participants

All manuscripts must comply with the privacy and confidentiality requirements outlined on the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit http://www.icmje.org/ethical_5privacy.html

When articles include reports of studies on human subjects, state in the Methods section that an appropriate institutional review board or ethics committee approved the study. Authors who do not have formal ethics review committees should follow the principles of the Declaration of Helsinki. In the Methods section, state that informed consent was obtained from subjects (specify written or verbal).

The principal author must state that if animals were used experimentally, permission was obtained from the appropriate committee(s), and that the animals were treated humanely and the standards conformed to those of current ethical animal research practices.

In addition, text and photographs should not reveal any identifying information unless it is essenti al for scientific purposes (in which case, consent should be obtained). Masking the subjects’ eyes in photographs is often insufficient to protect their identity.

ETHICAL CONSIDERATIONS IN THE CONDUCT AND REPORTING OF RESEARCH:

PROTECTION OF HUMAN SUBJECTS AND ANIMALS IN RESEARCH*

When reporting experiments on human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. When reporting experiments on animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed.

*This portion of the Instructions for Authors has been quoted directly from the Uniform Requirements for Manuscripts Submitted to Biomedical Journals website. For more information, visit www.icmje.org/ethical_6protection.html

PERMISSIONS

Figures, tables, and text taken from other sources must be accompanied by a written statement from both author and publisher, granting permission for reproduction Include written permission from authors to cite unpublished data or papers still in press.

PAGE PROOFSPage proofs will be sent to the (one) corresponding author as designated when the manuscript was uploaded to Manuscript Central. It is the corresponding author’s responsibility to share the page proofs with co-authors and to coordinate all authors’ corrections into one proof. The Publisher will not accept corrections from multiple authors.

Once a paper is accepted for publication, changes in authorship in the page proof stage are NOT permitted under any circumstance.

REPRINTS

Reprints may be ordered by following the special instructions that will accompany page proofs, and should be ordered at the time the corresponding author returns the corrected proofs to the Publisher. Reprints ordered after an issue is printed will be charged at a substantially higher rate.

Does your research funder have an open access mandate or would you like to expand the dissemination of your research?

The Liebert Open Access option enables authors to publish open access in our esteemed subscription-based journals.

The benefits of Liebert Open Access include:

- High visibility; open access articles are freely available online upon publication

- You retain copyright with the open access license allowing broad dissemination of your research

- You can freely share your article in repositories and research networks without restrictions

- Easy compliance with open access mandates

- Rigorous editorial and peer-review

- Targeted email announcement featuring a direct link to article

Identification and Marketing Open access articles are listed with an OA icon in journal tables of content (TOC), TOC alerts, and in marketing announcements. Open access articles are highlighted and promoted in targeted email announcements to thousands of research leaders in your field.

Copyright and Licensing If you choose to publish with open access, you will retain copyright of your article and a Creative Commons license will be applied. The liberal Creative Commons Attribution 4.0 (CC-BY) license is the default open access license used at Mary Ann Liebert, Inc., publishers. The CC-BY license permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

At this time we allow authors to choose between the CC-BY or CC-BY-NonCommercial license. A limited number of journals offer NonCommercial licenses exclusively.

Ordering Open Access Once your article has been accepted for publication in a journal, you will receive an email with information on ordering Liebert Open Access. If you would like more information about Liebert Open Access or would like to order open access, please email openaccess@liebertpub.com.

Publishing open access includes an article publication charge (APC) and authors are asked to fill out a short open access order form. You can pay by credit card or receive an invoice to be returned with payment or via bank transfer. Please remember that traditional subscription journals can carry mandatory or optional author fees. The Liebert Open Access APC does not cover or replace existing publication or author fees.

Publishing biomedical or biotechnology research?Biomedical researchers should consider publishing inBioResearch Open Access, a fully open access peer-reviewed journal dedicated to publishing top research in the biomedical and biotechnology fields. For details, please visit the information for authors on the journal website.

*Please note that PubMedCentral, not the Publisher, has sole control over when the paper is made live on PMC.

Is your institution a member of the Liebert Author Advocacy Program?

The Liebert Author Advocacy Program (LAAP)provides valuable membership benefits for OA publication to institutional and funding organizations, and supports global funding mandates. Authors who are affiliated with LAAP member institutions receive all the valuable benefits of Liebert OA article publication, and more.

NIH Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final accepted paper (after copy-editing and proofreading) to PubMed Central (PMC) on behalf of the authors. Authors need not take any action. The manuscript's public access posting on PMC will occur 12 months after final publication. This service is provided free of charge. Please note that authors may not deposit manuscripts directly to PMC or other sites without permission from Mary Ann Liebert, Inc.

Publishing in Subscription Journals

By signing the copyright transfer statement, authors still retain a set of rights that allow for self-archiving.

Authors may archive their preprint manuscripts (version prior to peer review) at any time without restrictions. Authors may archive their postprint manuscripts (accepted version after peer review) in institutional repositories, preprint servers, and research networks after a 12 month embargo. The 12 month embargo period begins when the article is published online. Postprints must not be used for commercial purposes and acknowledgement must be given to the final publication, and publisher, by inserting the DOI number of the article in the following sentence: “Final publication is available from Mary Ann Liebert, Inc., publishers http://dx.doi.org/[insert DOI]”. Authors may archive on their personal website without an embargo provided their manuscript is updated with an acknowledgement to the publisher copyright and final published version.

The final published article (version of record) can never be archived in a repository, preprint server, or research network.

Publishing Open Access

Authors that wish to easily comply with funder or institutional open access mandates should consider publishing open access. Liebert Open Accessoption allows authors to make their research freely available online without restrictions. Additionally, Liebert Open Access option allows authors to retain copyright, archive and share the final published version of their article without restrictions. To publish open access please email openaccess@liebertpub.com or visit Liebert Open Access for more information.

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.

Biotechnology Law Report

The leading journal devoted to the evolving body of law and government regulation concerning biotechnology, particularly in the industries in which new products from these technologies are developing the most rapidly.